We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MilliporeSigma has launched a new, high-purity synthetic cholesterol product, nine months ahead of schedule to meet high demand for lipids, a key component of mRNA-based vaccines and therapeutics.